Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at BMO Capital Markets

BMO Capital Markets started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note issued to investors on Friday, Marketbeat reports. The firm issued an outperform rating and a $63.00 price target on the stock.

Several other equities research analysts have also recently issued reports on JSPR. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research note on Monday, September 9th. Royal Bank of Canada cut their price target on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Finally, Evercore ISI reiterated an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $73.38.

Jasper Therapeutics Trading Up 4.4 %

Jasper Therapeutics stock opened at $22.48 on Friday. The stock has a market cap of $337.20 million, a P/E ratio of -4.74 and a beta of 2.18. The company has a fifty day simple moving average of $20.54 and a 200-day simple moving average of $20.90. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Samsara BioCapital LLC increased its stake in Jasper Therapeutics by 11.4% in the third quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Braidwell LP acquired a new position in Jasper Therapeutics in the third quarter valued at $9,091,000. Ally Bridge Group NY LLC increased its stake in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the period. State Street Corp increased its stake in shares of Jasper Therapeutics by 12.3% during the third quarter. State Street Corp now owns 214,883 shares of the company’s stock worth $4,042,000 after acquiring an additional 23,564 shares during the period. Finally, Fernwood Investment Management LLC increased its stake in shares of Jasper Therapeutics by 6.9% during the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock worth $995,000 after acquiring an additional 3,427 shares during the period. 79.85% of the stock is currently owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.